Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research
DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Society for Clinical Research Sites (SCRS) and Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), are pleased to announce Fortrea's sponsorship of the SCRS Collaborate Forward working group.
Comprising 16 leading Global Impact Partner organizations, the Collaborate Forward working group will explore and develop best practices to reduce administrative burdens across the clinical research ecosystem. The group is committed to fostering transparency and collaboration to tackle challenges faced by clinical research sites. By improving internal processes, it aims to make sites more sustainable and trials more efficient—ultimately leading to a smoother experience for patients.
Fortrea's sponsorship marks a significant investment in fostering industry-wide innovation and reflects the company's dedication to placing sites at the forefront of clinical trial planning.
'We are excited to partner with SCRS to launch and support this working group,' said Mike Clay, senior vice president of Global Project Delivery at Fortrea. 'Clinical trials are becoming increasingly complex, and the industry faces mounting pressure to accelerate innovation for patients. We believe that collaboration with clinical research sites is key to unlocking efficiencies and productivity gains that will streamline the clinical trial process. This initiative will develop tangible solutions that clinical study sponsors, CROs, vendors, sites and patient advocacy groups can rally behind. As a leading CRO, we are proud to be at the forefront of this effort, ensuring that sites remain central to driving progress and fostering greater industry-wide collaboration to bring life-changing treatments to patients faster.'
'Clinical research requires a unique interdependency to generate the best outcomes. Collaborate Forward will share partnership successes that impact the people, process and technology improving clinical research today,' added Sean Soth, senior vice president, Strategy and Global Business Partnerships, SCRS. 'We are pleased to welcome Fortrea as the charter sponsor of Collaborate Forward. This partnership underscores the value of cross-industry collaboration and the collective effort needed to drive meaningful progress in creating a more connected and efficient clinical trial ecosystem.'
Collaborate Forward will initially focus on study startup, showcasing the advantages of collaboration through compelling stories, case studies and data-driven insights. The group will convene regularly to exchange insights, assess industry trends and develop pragmatic tools that sponsors and CROs can implement within their organizations. Updates on the working group's progress will be shared throughout 2025 via SCRS Site Solutions Summits and publications, highlighting key findings and collaborative achievements.
SCRS invites sponsors and CROs committed to site sustainability to join this effort and contribute to shaping a more effective and synergistic clinical research landscape. For more information on how to participate, please contact Brian Egan.
About The Society for Clinical Research Sites
The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 11,000 research sites globally, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Learn more and get involved at myscrs.org. Our voice. Our community. Your success.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).
SCRS Contacts:
Marissa Hill (Media) – 267-865-3296, marissa.hill@myscrs.orgBrian Egan (Media) – 518-207-6965, brianeegan@gmail.com
Fortrea Contacts:
Galen Wilson (Media) – 703-298-0802, media@fortrea.comKate Dillon (Media) – 646-818-9115, kdillon@prosek.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
High Yield and Low Stress: 2 Dividend ETFs That Are Built for Passive Income
Key Points Statistical evidence supports the idea that these two ETFs can simultaneously grow capital and generate income. Maximum monthly drawdowns are less than the benchmark's performance, and so is the risk as defined by standard deviation. These ETFs do relatively best when benchmark indexes are highly volatile but still make money in bull markets. 10 stocks we like better than JPMorgan Equity Premium Income ETF › The JPMorgan Equity Premium Income ETF (NYSEMKT: JEPI) and JPMorgan Nasdaq Equity Premium Income ETF (NASDAQ: JEPQ) have garnered significant investor attention, in part due to their trailing-12-month dividend yields of 8.2% and 11.2%, respectively. Moreover, they offer monthly income, making them a favorite among passive income investors. As such, it would be interesting to share some modeling of their performance to see if they do offer investors a way to a relatively low-volatility strategy that practically guarantees a monthly income. (Keep in mind dividends can always be cut.) Introducing two JPMorgan ETFs The first thing to understand about these two exchange-traded funds is that they are not tailored to invest in dividend stocks. Instead, they both follow the same strategy of investing up to 80% of net assets in equities (stocks), with the only difference being that the Equity Premium ETF focuses on S&P 500 stocks while the Nasdaq Equity Premium ETF focuses on stocks in the Nasdaq-100. As noted above, the stocks are not explicitly selected for their dividend yield, an essential point because high-yield equity-focused ETFs often involve concentrating holdings in sectors with high yields. The remaining net assets, up to 20%, are invested in equity-linked notes (ELNs) that follow a strategy of selling call options on the indexes that the two ETFs benchmark -- S&P 500 and Nasdaq-100, respectively. A call option is the right to buy shares of the index at a specified price (the strike price) and is bought by bullish investors. The seller of the call options (in this case the ETF) receives a premium from the buyer. However, if the index increases significantly, the option is exercised, and the ELN typically incurs a loss. Conversely, when the index experiences a small gain, stays flat, or loses value, the option isn't exercised. The idea is that an anticipated net profit in premiums collected from the ELNs, combined with some dividend income from stock holdings, will generate sufficient income for distributions to be paid to shareholders under any condition, particularly in the event of a substantial increase in the index. And note that the upside is limited (gains less than the market), but the downside is also restricted. This table lays out how the portions of the ETFs will perform based on how the underlying index performs in a month. Monthly Index Performance Strong Gain Moderate Gain Moderate Loss Strong Loss Equities (At least 80% of the ETF assets) Strong Gain Gain Loss Strong Loss ELNs (Up to 20% of the ETF's assets) Loss Profit Profit Profit Overall Gain, but less than the market Gain, but less than the market Slight profit/slight loss Loss, but less than the market Author's analysis. What the ETFs need to do to demonstrate they work Before I throw charts at you, it's worth noting that the proof of the strategy working includes: The ETF should have a lower volatility than the index (measured here by the standard deviation of monthly returns). The ETFs should have relatively low maximum monthly drawdowns because passive investors usually do not want to lose a significant amount in any one month. The strategy should demonstrate a high coefficient of determination, or R^2, indicating that the independent variable (in this case, the benchmark index) is primarily responsible for determining the outcome. Performance consistent with the outcomes outlined in the table above. That said, here are the charts comparing the monthly index performance to the ETF's performance. Both sets of data include reinvestment of dividends. First, here's the JPMorgan Equity Premium Income ETF. And now the JPMorgan Nasdaq Equity Premium Income ETF. A few conclusions can be drawn from the data, along with some additional calculations. The monthly standard deviation of the S&P 500 over the period is 4.7%, compared to 3.1% for JEPI, indicating lower volatility returns. The monthly standard deviation of the Nasdaq-100 over the period is 5.7%, compared to 4.2% for JEPQ, indicating lower volatility returns. Both ETFs exhibit high R^2 values, indicating a consistency of outcome from the strategy. The three most significant monthly drawdowns for JEPI are -6.4%, -4.2%, and -4.1%. The three most significant monthly drawdowns for JEPQ are -8.7%, -6.8%, and -6.6%. In general, the strategy is effective, generating a collection of positive returns when the indices report moderate gains and losses. The downside is limited compared to the index when the market declines significantly, and the upside is limited when the indexes perform well. What it means to passive investors Both indices have performed very well over the periods, with an average monthly gain of 1.5% on the S&P 500 and 1.8% on the Nasdaq; therefore, the ETFs have understandably underperformed. However, there's no guarantee that these conditions will continue, and these ETFs have demonstrated lower volatility returns while maintaining substantial dividends for those seeking monthly income. As such, they are excellent options for those seeking to generate passive income across a range of market conditions. Should you invest $1,000 in JPMorgan Equity Premium Income ETF right now? Before you buy stock in JPMorgan Equity Premium Income ETF, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and JPMorgan Equity Premium Income ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $663,630!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,695!* Now, it's worth noting Stock Advisor's total average return is 1,071% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 JPMorgan Chase is an advertising partner of Motley Fool Money. Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase. The Motley Fool has a disclosure policy. High Yield and Low Stress: 2 Dividend ETFs That Are Built for Passive Income was originally published by The Motley Fool
Yahoo
2 hours ago
- Yahoo
£20k to invest? Consider these passive income stocks to target £2k a year
The first rule of income investing is to remember that dividends from stocks are never guaranteed. For this reason, it's important to build a diversified portfolio that can weather individual shocks and still pay a healthy passive income now and over the long term. Here's an example of what a well-diversified portfolio might look like: Dividend stock Forward dividend yield Global X Nasdaq 100 Covered Call ETF 11% Chelverton UK Dividend Trust 9.4% iShares World Equity High Income ETF (LSE:WINC) 9.7% In total, these investment trusts and exchange-traded funds (ETFs) provide exposure to more than 450 different companies. These span a multitude of regions and sectors, reducing concentration risk and helping to provide a more stable return across the economic cycle. What's more, they have enormous dividend yields, as the table shows. To give you an example of the passive income they can throw off, a £20,000 lump sum invested across them could provide a £2,000 dividend income this year alone. I'm also confident they can grow dividends over time. Here's why I think they're worth considering today. Top fund Tech stocks aren't famed for their enormous dividend potential. But the Global X Nasdaq 100 Covered Call ETF works by purchasing Nasdaq shares and selling covered calls on them, redistributing the income to the fund's shareholders. This fund provides an added bonus to its holders: it pays monthly distributions, giving investors access to their cash earlier. It can thus be a useful tool for accelerating compounding by shortening intervals between reinvestments. Monthly distributions here have been paid for the last 11 years. One downside is that there's limited price appreciation potential, because any price growth above strike prices is forfeited. This can put it at a disadvantage to standard Nasdaq tracker funds. But for dividend hunters, this may be a price worth paying. Dividend trust As its name implies, the Chelverton UK Dividend Trust is focused on generating income from British equities. This geographical strategy carries greater concentration risk than more global funds. But given the London stock market's strong dividend culture, it also has its advantages. It's also important to note that, on balance, this trust is still well diversified despite its UK focus. It invests in a range of industries like financial services, consumer goods, energy, and mining. Furthermore, its capital is evenly distributed, further reducing the threat of individual shocks on overall returns. Hargreaves Services is currently its single largest holding, at 3.5%. Global leader To my mind, the iShares World Equity High Income fund offers a brilliant blend of safety and exciting income potential. Unlike the other high-yield trusts and ETFs I've described, its holdings aren't confined to specific territories. In total, it holds shares in roughly 300 global equities spanning financial services, information technology, telecoms, healthcare, and consumer goods. This broad range protects investors from nasty localised shocks. But this is not all — its two largest single holdings are cash and US Treasuries, accounting for 6.3% and 5.7% of the portfolio respectively. This provides an added layer of robustness. The lion's share of its capital is stashed in the equity market, though. And so it is still highly exposed to stock market movements. But given the long-term resilience of global shares, I believe it's a top dividend stock to consider. The post £20k to invest? Consider these passive income stocks to target £2k a year appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
2 hours ago
- Business Insider
Kyivstar Hopes to Shine in New York as Ukraine Peace Talks Begin
Shares in Ukrainian mobile operator Kyivstar will start trading in New York today hoping that peace talks to end the devastating war in the country will significantly boost the company's value. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Chief executive officer Oleksandr Komarov said ahead of the Nasdaq listing that the summit between President Trump and Russian leader Vladimir Putin in Alaska, scheduled for August 15 th, would help drive investment into Ukraine if an end to the three-year war is found. Invest in Recovery 'We will be the best asset for the international investment community to invest in Ukraine, to invest in the Ukrainian recovery, to invest in the Ukrainian support,' Komarov said. Komarov said the company chose Nasdaq, where its Dubai-based parent VEON (VEON) is also listed, over London or Warsaw because it is even more important to 'strengthen the link between the United States and Ukraine rather than between Ukraine and Europe.' VEON shares were up 1.6% in pre-market trading. The company has also strengthened its U.S. ties during the conflict, appointing former U.S. Secretary of State Mike Pompeo to its board and signing a deal with Elon Musk's Starlink for satellite services. Kyivstar, which has been given a pro forma valuation of $2.3 billion, carried out the listing by merging with fintech entrepreneur Betsy Cohen's Cohen Circle special purpose acquisition company (SPAC). The company raised $178 million, confirming earlier reports that it expected up to $200 million. VEON will retain a majority stake in the mobile operator. People's IPO The company has previously stated that it has had extremely strong support for the Kyivstar listing from U.S. authorities, Ukraine and the European Union. Indeed, it has described the listing as 'the people's IPO', hoping that investors around the world would show their support for Ukraine. Kyivstar is the market-leading mobile operator in Ukraine with 24 million subscribers. Analysts agreed that the narrative around the deal was built around Ukraine's postwar reconstruction and digital infrastructure's role in that recovery. However, investors will also likely question the strength of that recovery and the likelihood of any peace deal between Ukraine and Russia holding over the long-term.
